Cubist Systematic Strategies, LLC Alector, Inc. Transaction History

Cubist Systematic Strategies, LLC

$15.8 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$4.19 - $6.23 $163,187 - $242,639	38,947 Added 73.11%	92,218 $418,000
Q1 2024 May 15, 2024	SELL	$5.69 - $8.08 $623,385 - $885,228	-109,558 Reduced 67.28%	53,271 $320,000
Q4 2023 Feb 14, 2024	BUY	$3.77 - $8.39 $577,609 - $1.29 Million	153,212 Added 1593.14%	162,829 $1.3 Million
Q3 2023 Nov 14, 2023	BUY	$5.2 - $8.77 $50,008 - $84,341	9,617 New	9,617 $62,000
Q1 2023 May 15, 2023	BUY	$5.85 - $9.84 $251,608 - $423,218	43,010 New	43,010 $266,000
Q3 2022 Nov 14, 2022	SELL	$8.19 - $13.2 $443,357 - $714,568	-54,134 Reduced 60.52%	35,311 $334,000
Q2 2022 Aug 15, 2022	SELL	$7.65 - $14.24 $247,133 - $460,023	-32,305 Reduced 26.53%	89,445 $909,000
Q1 2022 May 16, 2022	BUY	$13.02 - $20.78 $446,703 - $712,941	34,309 Added 39.24%	121,750 $1.74 Million
Q4 2021 Feb 14, 2022	BUY	$19.35 - $25.54 $266,836 - $352,196	13,790 Added 18.72%	87,441 $1.81 Million
Q3 2021 Nov 15, 2021	BUY	$21.65 - $39.49 $1.27 Million - $2.32 Million	58,697 Added 392.52%	73,651 $1.68 Million
Q2 2021 Aug 16, 2021	BUY	$15.5 - $22.48 $231,787 - $336,165	14,954 New	14,954 $311,000
Q1 2021 May 17, 2021	SELL	$14.84 - $22.23 $225,849 - $338,318	-15,219 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$9.4 - $16.7 $534,333 - $949,294	-56,844 Reduced 78.88%	15,219 $230,000
Q3 2020 Nov 16, 2020	BUY	$10.54 - $24.96 $563,078 - $1.33 Million	53,423 Added 286.6%	72,063 $759,000
Q2 2020 Aug 14, 2020	BUY	$21.87 - $33.11 $47,261 - $71,550	2,161 Added 13.11%	18,640 $456,000
Q1 2020 May 15, 2020	BUY	$16.25 - $35.28 $267,783 - $581,379	16,479 New	16,479 $398,000

Others Institutions Holding ALEC

# of Institutions

168

Shares Held

57.8M

Call Options Held

146K

Put Options Held

90.8K

View Full List

About Alector, Inc.

Ticker ALEC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,563,904
Market Cap $159M
Description
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...

More about ALEC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.

Account